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     SUMMARY
The purpose was to establish simple statistics of the effects of lassa fever in northern part of 
Edo State, Nigeria. Lassa fever activity in the northern part of Edo state, Nigeria, was confirmed 
in 2004 by laboratory analysis of samples sent to Bernhard–Nocht Institute (BNI) for Tropical 
Medicine Hamburg, Germany. The published report of that study is re-analysed to determine 
in statistical terms, what the values presented in percentages translate to in number of persons 
in the hospital and the area. In the year 2004, 12,000 persons presented with febrile illness at 
Irrua Specialist Teaching Hospital (ISTH), Irrua; 832 (6.5%) had lassa fever confirmed by reverse-
transcriptase-polymerase chain reaction (RT-PCR).  4,096 (32.26%) of those with febrile illness 
had acute infection as they tested positive for IgM antibody.   333 (33.33%) of about 1000 staff 
of the hospital had sub-clinical infection as they tested positive for IgG and negative for IgM 
antibody. At least 208 of the 832 patients (25%) of the hospital with confirmed lassa fever must 
have died in the year 2004. 967 (5.9%) of relatives or members of the public who had contact with 
infected persons had confirmed lassa fever. 555 (66.67%) of those with confirmed lassa fever 
are close relatives. The epidemics occur in clusters of households, houses, streets or villages. It 
is concluded that high lassa fever activity in the area has wider effects than what is observed 
in hospital admitted patients. Further seroepidemiological survey involving large population 
sample in the area should be carried out to establish more accurate seroepidemiological data 
on lassa fever. This study is expected to impact positively on the generation of political priority 
for the control of lassa fever in Nigeria.
    
    [Afr J Health Sci. 2010; 17:52-56]
Introduction
Lassa fever is an infection caused by lassa virus, a 
single stranded RNA virus.  Lassa fever is a type of 
viral haemorrhagic fever with very high mortality rate 
in hospitalised patients.  The disease is endemic in 
West Africa including Nigeria.  The earliest record of 
the disease was in the 1950s but the virus was isolated 
by the Centre for Disease Control (CDC), Atlanta, 
USA, in 1969, from a sample taken from a missionary 
worker in Lassa village in northern Nigeria.  A rat that 
is common in endemic areas, known as mastomys 
natalensis is the natural host of the disease.[1,2,3] 
Contacts with the rats including contamination of food 
by saliva, urine, excreta or other body fluid of the rat 
lead  to the infection.  Nosocomial transmission may 
occur through droplets by person-to-person contact or 
the contamination of needles. The symptoms and signs 
of the disease are similar and almost indistinguishable 
from other causes of fever in endemic areas such as 
malaria, typhoid, yellow fever, upper respiratory tract 
infection and other viral illnesses. The incubation 
period is 6 to 21 days.  The symptoms and signs 
include fever, nausea and vomiting, chest pain, 
periorbital oedema, puffy face, puffy checks, oedema, 
dehydration, retrosternal pain, conjunctival injection, 
fainting attacks, bleeding from orifices, hypotension, 
shock and coma.[1-8] Other signs are pleural effusion,
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ascites, cerebral oedema, adult respiratory distress 
syndrome and poor renal function [1-5] Simple 
diagnostic tests like bleeding time, whole blood clotting 
time and urinalysis may be helpful but non-specific. 
Thrombocytopaenia and lymphocytopaenia also 
occur in the disease. Other specific tests for accurate 
diagnosis are expensive and not generally available 
in the countries where the lassa fever is endemic. 
These tests include antibody IgG and IgM estimation, 
enzyme-linked immunosorbent assay (ELISA) for 
lassa virus antigen, reverse transcriptase polymerase 
chain reaction, immunofluorescence test and viral 
isolation. [1,2,3] The treatments include supportive 
measures like correction of hypotension, electrolyte 
and fluid replacement. Vaccines are expensive and not 
generally available or acceptable [4]. Surveillances 
include identification of close contacts for three weeks 
from the onset of the illness as well as the search for 
unreported and undiagnosed cases. Close contact of 
people in traditional burial ceremonies of infected 
corpses should be avoided.  Overcrowding in hospitals 
especially in undiagnosed cases can lead to spread to 
other patients, staff and visitors in the hospitals. [1-8] 
Several cases of viral haemorrhagic fever from the 
northern part of Edo State, including Ekpoma, Uromi, 
Irrua, Igueben, Iruekpen, Igarra, Ibillo, Ozalla, Ubiaja, 
Agenebode, Auchi, Afuze, Akoko Edo, Ewu, Okpella 
and environs have been treated at the University of 
Benin Teaching Hospital, Benin City, from 1970 to 
2000 with high fatality.  There was no specific mention 
of lassa fever in all these years and no specific drug 
treatment or precautionary measure was available or 
adopted. With the establishment of Nigerian federal 
government-sponsored Irrua Specialist Teaching 
Hospital, Irrua, in the northern part of Edo State in 
1992 (a teaching hospital for Ambrose Alli University, 
Ekpoma), several highly trained and motivated 
specialist doctors became available for teaching, 
research and treatment of diseases. The identification 
of large number of mastomys natalensis, the rat that is 
the natural host of the lassa fever virus led to attempts 
to identify the virus in patients with febrile illness in 
the area [5]. Careful history, clinical examination and 
assessment of sufferers with febrile illness that had 
periodic outbreaks led to the clinical diagnosis of lassa 
fever and requests for the equipment of the hospital or 
assessment of the samples from patients for specific 
diagnosis of lassa fever.[1,6,7,8] Clinical diagnosis 
was proven, remaining laboratory  diagnosis including 
viral isolation.  The federal government of Nigeria 
responded by erecting a lassa fever ward in the hospital
and provided a project vehicle and ribavirin at no 
cost. Since then, patients with lassa fever have had 
some benefits of specific drug treatment. However, 
serological tests and viral isolation facilities were not 
available to define the magnitude of the problems in 
accurate statistical terms. This partly inhibited the 
development of political priority for the control of 
the infection since facts cannot be presented in simple 
statistical terms. In 2003, this problem was overcome 
with the help of a research team from BNI, Hamburg, 
Germany. 
Materials and Method
In the years 2001, 2003 and 2004, large numbers of 
suspected outbreaks of lassa fever in the area led to 
a call from the hospital for special assistance. [6,7,8] 
To confirm lassa fever activity, samples were collected 
from ISTH between 2003 and 2004 involving patients 
suspected to have the disease, healthy contacts 
and some hospital staff. [8] These were sent to the 
Department of Virology, University of Lagos, Nigeria. 
After initial tests, the samples were later sent to 
Bernhard-Nocht Institute (BNI) for tropical medicine, 
Hamburg, Germany.  BNI is a WHO collaborating 
centre for Arbovirus and Haemorrhagic fever reference 
and research. The result of the study was published [8] 
with isolation of the lassa virus including phylogenetic 
lineage and antibodies detection in healthy contacts 
and hospital workers. A total of 60 serum samples 
were collected and tested and the summary shows that 
6.5 % of patient with febrile illness that were tested 
had confirmed lassa fever using reverse-transcriptase 
polymerase chain reaction (RT – PCR) and polymerase 
chain reaction (PCR).  Serological tests for lassa 
virus-specific immunoglobulin G (IgG) and IgM were 
performed by indirect immunofluorescence assay by 
using cells infected with lassa virus strain Josiah.  The 
virus was isolated in biosafety level 4 laboratories at 
BNI, Hamburg, Germany. 
This study consists of re-analyses of the findings to 
find out what the figures from the results of this study 
amounted to in the number of persons in the hospital 
and the area concerning lassa fever activity.
Results
The report by the study at BNI is the proof of lassa 
fever activity in the area (Table 1).  The magnitude of 
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the problems in facts and figures is shown in this result 
which is a re-analysis of the report. This study is to find 
out what the results of the 60 samples [8] translate to 
in normal daily life of the inhabitants of northern part 
of Edo State and Nigeria.  This is shown as follows:
1. The number of patients seen at ISTH in 2004 
was 16,000 and 80% of them had febrile illness [8] 
meaning that, 12,800 patients presented with febrile 
illness in the hospital in that year alone.
2. Two persons (6.5%) out of 31 persons with 
febrile illness that were tested had PCR-confirmed 
lassa fever [8] (Table 1).  12, 800 patients had febrile 
illness and (6.5%) of this means that 832 patients 
had confirmed lassa fever in that year from ISTH 
alone.  This excluded those who visited other health 
institutions.  If we assume 50% mortality since the 
number was not differentiated into children, elderly, 
pregnant women, adult and those not admitted in the 
hospital, this means that at least 384 persons died in 
that year from Lassa fever in Irrua Specialist Teaching 
Hospital alone.
3. Ten out of 31 patients (32.26%) with febrile 
illness had IgM antibody with or without IgG 
seropositivity for lassa fever virus [8] (Table 1). 
Therefore 32.26% of patients with febrile illness have 
Table 1. Lassa virus-specific findings in serum samples from Irrua SpecialistTeaching Hospital, Edo,Nigeria* (Table from Omi-
labu et al8) 
  Patient    RT-PCR  IgM titer IgG titer
  Patients with fever  (n=31).   
  04-10   Positive  - -
  04-02   Positive   1:40  -
  04-51   -  1:160  -
  04-34   -  1:40  -
  04-03   -  1:,>20,480 1:20,480
  04-05   -  1:320  1:20,480
  04-01   -  1:160  1:10,240
  04-08   -  1:80  1:20,480
  04-33   -  1:20  1:640
  04-52   -  1:160  1:40
  04-53   -  1:40  1:40
  Contact persons (n=17)   
  04-04   positive  1:20  1:>20,480
  03-04   -  1:160  1:80
  04-11   -  - 
  Hospital staff (n=12)   
  04-31   -  -  1:80
  04-32   -  -  1:80
  04-17   -  -  1:80
  04-20   -  -  1:20
*Data not shown for patients whose samples were negative in all tests.
positive IgM antibody.  Presence of IgM antibody 
indicates acute infection.  This translates to 4,096 
persons that came to ISTH that year with febrile illness 
as having recent infection of lassa fever.  This number 
excluded all patients who went to native doctors, 
herbal centres, other hospitals and clinics or who did 
not go anywhere or who may have died at home.
4. IgG in the absence of IgM was detected in 1 of 
the 17 contacts (5.9%) tested [8] (Table 1). This means 
previous exposure to the virus.  5.9% of tenants, co-
tenants, close students, room mates, class mates and 
relations of patients with lassa fever were infected 
with the disease.  In Africa, where  polygamy, poor 
housing, overcrowding, high social support for sick 
persons and relations of death person are rampant, the 
real number will translate to hundreds of thousands of 
persons
5. IgG without IgM was detected in 4 of the 12 
health care workers (33.33%)   tested [8] (Table 1). 
Therefore since the number of hospital workers at ISTH 
is at least 1000, this translates to 333 of hospital workers 
having subclinical infection or having recovered from 
the disease 6. One of 17 asymptomatic contact 
persons (5.9%)   had PCR-confirmed lassa fever at the 
time of sampling [8] (Table 1).  This means that 5.9% 
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of contacts had confirmed lassa fever even though 
these persons were asymptomatic.  In most African 
communities, at least 4 persons attend to a sick person, 
at least 4 persons sleep in a room or live closely in 
a house (the average student population in Ekpoma 
University in a room is 8 per room),   we assume that 
1 infected person would have had at least 4 contacts. 
Since from (3) above, 4,096 persons that came to ISTH 
had recent infection of lassa fever, we extrapolate 
that 4 contacts will amount to 16,384 members of the 
community.  5.9% of 16,384 will give 967 persons. 
Therefore 967 persons that are associated or had 
contacts with infected persons in ISTH in 2004 will 
have confirmed lassa fever.
7. Two (66.67%) of the 3 persons with confirmed 
PCR – positive for lassa fever were sisters living in 
the same house, had identical sequence of lassa fever 
showing closely related strains of lassa fever virus [8] 
Table 1.  This also shows that 66.67% of lassa fever 
infection will occur in close relations possibly living in 
the same house.  This is the trend observed in real life 
at ISTH as the epidemics occur in clusters of houses or 
villages.
8. Lassa fever circulating in the northern part of 
Edo State, Nigeria, (Nig 04 – 010) upon phylogenic 
analysis confirmed that it belongs to phylogenetic 
lineage II which is consistent with lassa virus strain 
circulating in the southern part of Nigeria with 
corresponding genetic and geographical origin.[8 ]
Discussion
Confirmation of lassa virus infection is a pre-requisite 
for ribavirin therapy. [1,2,3] Ribavirin is not always 
available in the hospital. Therefore health workers 
while saving lives do what appears as attempting 
suicide, since the mortality rate is high without drug 
treatment in confirmed cases and 33.33% of health care 
workers at ISTH were exposed to the disease [8].  There 
is no laboratory for specialised test for lassa fever in 
ISTH, patients are dying every day from the infection. 
This study shows that 832 patients had confirmed lassa 
fever in 2004 and this figure is 6.5% of patients with 
febrile illness [8] (Table 1).  Much money was spent on 
Avian Flu in Nigeria yet only one confirmed mortality 
was recorded.  Here, in northern Edo State, where 
lassa fever is ravaging youths, children and pregnant 
mothers and there is poor response in terms of drug 
supply or even advocacy.
Each year at least 32.26% (4, 096) of patients with 
febrile illness that come to ISTH have lassa fever.  This 
figure may even be more than malaria and tuberculosis 
or HIV/AIDS.  At least 5.9% of asymptomatic contacts 
had lassa fever confirmed and isolated from seven 
samples. [8] These figures should alarm all that are 
concerned that none is safe because if the asymptomatic 
contact travels to areas where lassa fever is not endemic 
such will not be treated for lassa fever since the drug 
is sent only to government hospitals in endemic areas 
of Nigeria.
Even though this study and the previous one [8] 
from which data was collected and extrapolated are 
limited in that they did not give mortality or fatality 
rate, or differentiate the infection into children, women, 
pregnant mothers or elderly, it has solidly confirmed 
the existence of an enormous problem.
We have undertaken this study as the authors agree 
with Shiffman [9,10,11,12] and other public policy 
researchers [13,14,15] that the existence of an indicator 
to mark the severity of the problem has a powerful 
effect of giving viability  to that which has remained 
hidden and is therefore one of the strongest factors that 
determine whether an issue rises to the attention of 
policy makers.  This study defined the clear message 
that the problem of lassa fever exists, it is killing 
inhabitants and visitors in the area and health care 
workers are at great risk.  Contacts of infected persons 
including travellers and health and aid workers are at 
great risk and there is the need for adopting multiple 
criteria and capacity building in tackling the menace of 
lassa fever in West Africa.[13,14] A stitch in time, they 
say, saves nine.  Attention is not paid to lassa fever in 
Edo State and in Nigeria as it deserves because there 
are not enough social entrepreneurs [15] and men of 
great calibre in Nigeria advocating for the prevention 
and treatment of the disease due mainly to its rural 
affectation and hence poor funding. [9,10,11,12] Since 
the deaths of leaders in Nigeria are not mostly from 
infection, there is tendency for leaders to ignore the 
great havoc of infectious diseases like lassa fever in 
Nigeria. [16] The breakdown of this result in simple 
statistical terms of its effect on the people is expected 
to generate the critically required international 
response which is so urgently needed in tackling lassa 
fever in West Africa and the world. [17] The fact that 
5.9% of contacts got the infection places great risks on 
international travel and tourism worldwide. The fact 
that 832 patients are infected with the virus means that 
the government should as a matter of urgency improve 
the deplorable drug supply [18,19] pattern especially 
as it concerns ribavirin availability. The magnitude of 
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the problem also emphasises the need for community 
involvement in decision making process [20] regarding 
preventive measures, health education and health-
seeking behaviours and vector eradication. Already 
a total of 24 confirmed lassa fever cases has been 
reported worldwide outside the West African sub-
region and this number excluded non-reported cases 
and contacts of the reported cases.
In conclusion, there is high lassa fever activity in 
the area with high rate of infection of contact persons. 
These figures which were derived from re-analysis of 
confirmed cases of lassa fever infection are expected 
to impact positively on the political priority for the 
control of lassa fever in Nigeria. The statistics from 
this study are also expected to serve not only for 
monitoring purposes but also act as a catalyst for 
action to all the stakeholders involved in the control of 
lassa fever at both local and international levels.  
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